*From the 2023 NIH Budget Hearing in May 2022 - Why NIH Leaders are Allowed to Discourage Use of Off-Patent Drugs While Collecting Royalties on New Products
10 months ago
4.68K
Rep. John Moolenaar Asks Why NIH Leaders are Allowed to Discourage Use of Off-Patent Drugs While Collecting Royalties on New Products
“What strikes me is you’re in a position where you say certain drugs don’t work, but then you can at the same time be getting royalties from other products.”
*From the 2023 NIH Budget Hearing in May 2022
https://twitter.com/thechiefnerd/status/1689649894410305536
@ChiefNerd
Loading 4 comments...
-
5:11
Asher Press
10 months agoNIH Discourages Off-Patent Drugs While Collecting Royalties on New Products! - Rep. John Moolenaar
212 -
2:36
KMTV
4 years agoLegislative bill would regulate pharmaceutical middle man
16 -
3:24:57
R.C. Davis
1 year agoHouse Committee on Energy and Commerce: Health Subcommittee Hearing: “Reauthorization of the Animal Drug User Fee Programs.” - March 30, 2023
27 -
2:28
NTD
3 years agoCongress Negotiating Lowering Drug Prices
828 -
6:00
One America News Network
3 years agoHealth Policy Expert Reveals Flaws of Drug Pricing Bill
9416 -
3:27
TheGoldwater
3 months agoRand Paul's Bill Requires NIH Scientists to Disclose Royalties they Receive from Drug Companies
36 -
14:00
TheRealTruthAboutHealth
6 months agoHow the 1962 Amendments Created a Big Pharma Cartel With Questionable Ethics
123 -
1:43
RightHereRadio
1 year agoBig Pharma Pimps Part 3: Buying Off The Judicial Branch To Rule In Favor Of Taking Their Products
1 -
1:58:04
The Union Herald
2 months agoSenate Judiciary Hearing on the Patent Eligibility Restoration Act
-
3:18
WFTS
1 year agoHow the prescription drug reform bill in Congress will impact you
1